Gael S Roth

10PUBLICATIONS
48CO-AUTHORS
Haematological tumoursPredictive and prognostic markersMolecular targetsTraditional Chinese medicine and treatmentsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Dec 26, 2022
Immunotherapy in hepatocellular carcinoma: How does underlying liver disease influence therapeutic strategy and outcomes?

Gael S Roth, François Villeret, Thomas Decaens

|Dec 23, 2022
Effect of Novel AKT Inhibitor Vevorisertib as Single Agent and in Combination with Sorafenib on Hepatocellular Carcinoma in a Cirrhotic Rat Model.

Keerthi Kurma, Ayca Zeybek Kuyucu, Gaël S Roth

|Nov 11, 2022
Structural and Socio-Spatial Determinants Influencing Care and Survival of Patients with a Pancreatic Adenocarcinoma: Results of the PANDAURA Cohort.

Gaël S Roth, Yohan Fayet, Sakina Benmameche-Medjahed

|Jul 12, 2022
SMYD3 Impedes Small Cell Lung Cancer Sensitivity to Alkylation Damage through RNF113A Methylation-Phosphorylation Cross-talk.

Valentina Lukinović, Simone Hausmann, Gael S Roth

|Apr 12, 2022
Safety and Efficacy of Transarterial Chemoembolization in Elderly Patients with Intermediate Hepatocellular Carcinoma.

Gael S Roth, Olivier Hernandez, Najeh Daabek

|Nov 06, 2021
GNS561, a clinical-stage PPT1 inhibitor, is efficient against hepatocellular carcinoma via modulation of lysosomal functions.

Sonia Brun, Eloïne Bestion, Eric Raymond

Pageof 2

Frequent Collaborators

6 joint publications

Thomas Decaens

3 joint publications

Zuzana Macek Jílková

2 joint publications

Patrice N Marche

1 joint publications

Hervé Lerat